GlassScriptPhysician profile
Musaberk Goksel
NPI 1174576490
$2,578.74
in general payments reported to CMS, 2019-2025
40 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $82.48 · 2022: $986 · 2023: $363 · 2024: $344 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.38 |
| Education | $293.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $435.53 | 2019-2023 | |
| Abbvie INC. | $328.22 | 2022-2024 | |
| Janssen Biotech, INC. | $165.50 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| Emd Serono, INC. | $161.57 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $129.97 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $125.36 | 2019-2023 | Lynparza |
| Genmab U.S., INC. | $125.00 | 2024 | Epkinly |
| Tempus Ai, INC | $82.69 | 2024 | |
| Genentech USA, INC. | $79.68 | 2022-2024 | Phesgo, Gavreto, Alecensa |
| Celgene Corporation | $78.89 | 2022-2023 | Pomalyst |
| Novartis Pharmaceuticals Corporation | $69.33 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.93 | 2019-2022 | |
| Novocure INC. | $53.32 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $52.43 | 2022 | |
| Sun Pharmaceutical Industries INC. | $48.84 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $47.85 | 2022 | |
| Ferring Pharmaceuticals INC. | $45.48 | 2019-2020 | |
| Seagen INC. | $40.73 | 2020-2022 | |
| Tolmar Pharmaceuticals, INC. | $40.71 | 2019 | |
| Exelixis INC. | $35.60 | 2022 | |
| Gilead Sciences, INC. | $31.69 | 2022 | |
| Daiichi Sankyo INC. | $29.60 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $29.00 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $26.44 | 2022 | |
| Glaxosmithkline, LLC. | $25.35 | 2022 | |
| Servier Pharmaceuticals LLC | $24.01 | 2022 | |
| Pfizer INC. | $22.38 | 2022 | |
| Lilly USA, LLC | $21.87 | 2022 | |
| Endo Pharmaceuticals INC. | $20.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.37 | 2022 | |
| G1 Therapeutics, INC. | $18.75 | 2022 | |
| Agios Pharmaceuticals, INC. | $18.65 | 2022 | |
| Incyte Corporation | $18.42 | 2022 | |
| Eusa Pharma (US) LLC | $17.79 | 2022 | |
| Taiho Oncology, INC. | $16.21 | 2022 | |
| Amgen INC. | $15.03 | 2023 | Xgeva, Vectibix, Nplate |
| Allergan, INC. | $12.55 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Musaberk Goksel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.